ResearcherHiroshima UniversityActive in the last 2 years
Shiro Oka
Matched on ORCID iD 0000-0002-1652-0743; OpenAlex author ID A5035255723. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 0, last author 2)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 26
2023: 2 papers · 2024: none · 2025: 1 paper · 2026: 3 papers
Papers 6
- Clinical outcomes and recurrence patterns in pancreatic ductal adenocarcinoma diagnosed at an early stage: insights from a multicenter cohort study in Japan. Last author DOI 10.1007/s00535-025-02340-x↗
- Minichromosome maintenance 4 is associated with poor survival and stemness of patients with pancreatic cancer. Co-author DOI 10.1007/s00795-025-00438-y↗
- Prognostic Impact of the Combined Use of CA19-9 and DUPAN-2 in Initially Unresectable Locally Advanced Pancreatic Adenocarcinoma. Co-author DOI 10.1245/s10434-026-20710-4↗
- Survival benefit of adjuvant therapy completion with early initiation for patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ags3.12898↗
- Expression of kinesin family member C1 in pancreatic ductal adenocarcinoma affects tumor progression and stemness. Co-author DOI 10.1016/j.prp.2022.154277↗
- Utility of Covered Self-Expanding Metal Stents for Biliary Drainage during Neoadjuvant Chemotherapy in Patients with Borderline Resectable Pancreatic Cancer. Last author DOI 10.3390/jcm12196245↗
Closest collaborators
The 25 strongest of 26 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Yasutaka Ishii · 5 shared papers, 2023–2026 · strength 1.17
- Paper Minichromosome maintenance 4 is associated with poor survival and stemness of patients with pancreatic cancer. DOI 10.1007/s00795-025-00438-y↗
- Paper Prognostic Impact of the Combined Use of CA19-9 and DUPAN-2 in Initially Unresectable Locally Advanced Pancreatic Adeno… DOI 10.1245/s10434-026-20710-4↗
- Paper Survival benefit of adjuvant therapy completion with early initiation for patients with pancreatic ductal adenocarcinom… DOI 10.1002/ags3.12898↗
- Kenichiro Uemura · 4 shared papers, 2023–2026 · strength 0.90
- Paper Prognostic Impact of the Combined Use of CA19-9 and DUPAN-2 in Initially Unresectable Locally Advanced Pancreatic Adeno… DOI 10.1245/s10434-026-20710-4↗
- Paper Survival benefit of adjuvant therapy completion with early initiation for patients with pancreatic ductal adenocarcinom… DOI 10.1002/ags3.12898↗
- Paper Clinical outcomes and recurrence patterns in pancreatic ductal adenocarcinoma diagnosed at an early stage: insights fro… DOI 10.1007/s00535-025-02340-x↗
- Sho Tazuma · 3 shared papers, 2023–2026 · strength 0.70
- Paper Minichromosome maintenance 4 is associated with poor survival and stemness of patients with pancreatic cancer. DOI 10.1007/s00795-025-00438-y↗
- Paper Prognostic Impact of the Combined Use of CA19-9 and DUPAN-2 in Initially Unresectable Locally Advanced Pancreatic Adeno… DOI 10.1245/s10434-026-20710-4↗
- Paper Expression of kinesin family member C1 in pancreatic ductal adenocarcinoma affects tumor progression and stemness. DOI 10.1016/j.prp.2022.154277↗
- Juri Ikemoto · 3 shared papers, 2023–2026 · strength 0.65
- Paper Prognostic Impact of the Combined Use of CA19-9 and DUPAN-2 in Initially Unresectable Locally Advanced Pancreatic Adeno… DOI 10.1245/s10434-026-20710-4↗
- Paper Clinical outcomes and recurrence patterns in pancreatic ductal adenocarcinoma diagnosed at an early stage: insights fro… DOI 10.1007/s00535-025-02340-x↗
- Paper Utility of Covered Self-Expanding Metal Stents for Biliary Drainage during Neoadjuvant Chemotherapy in Patients with Bo… DOI 10.3390/jcm12196245↗
- Takumi Harada · 2 shared papers, 2025–2026 · strength 0.51
- Paper Prognostic Impact of the Combined Use of CA19-9 and DUPAN-2 in Initially Unresectable Locally Advanced Pancreatic Adeno… DOI 10.1245/s10434-026-20710-4↗
- Paper Survival benefit of adjuvant therapy completion with early initiation for patients with pancreatic ductal adenocarcinom… DOI 10.1002/ags3.12898↗
- Yoshiaki Murakami · 2 shared papers, 2025–2026 · strength 0.51
- Paper Prognostic Impact of the Combined Use of CA19-9 and DUPAN-2 in Initially Unresectable Locally Advanced Pancreatic Adeno… DOI 10.1245/s10434-026-20710-4↗
- Paper Survival benefit of adjuvant therapy completion with early initiation for patients with pancreatic ductal adenocarcinom… DOI 10.1002/ags3.12898↗
- Tatsuaki Sumiyoshi · 2 shared papers, 2025–2026 · strength 0.51
- Paper Prognostic Impact of the Combined Use of CA19-9 and DUPAN-2 in Initially Unresectable Locally Advanced Pancreatic Adeno… DOI 10.1245/s10434-026-20710-4↗
- Paper Survival benefit of adjuvant therapy completion with early initiation for patients with pancreatic ductal adenocarcinom… DOI 10.1002/ags3.12898↗
- Kenjiro Okada · 2 shared papers, 2025–2026 · strength 0.51
- Paper Prognostic Impact of the Combined Use of CA19-9 and DUPAN-2 in Initially Unresectable Locally Advanced Pancreatic Adeno… DOI 10.1245/s10434-026-20710-4↗
- Paper Survival benefit of adjuvant therapy completion with early initiation for patients with pancreatic ductal adenocarcinom… DOI 10.1002/ags3.12898↗
- Ryuta Shintakuya · 2 shared papers, 2025–2026 · strength 0.51
- Paper Prognostic Impact of the Combined Use of CA19-9 and DUPAN-2 in Initially Unresectable Locally Advanced Pancreatic Adeno… DOI 10.1245/s10434-026-20710-4↗
- Paper Survival benefit of adjuvant therapy completion with early initiation for patients with pancreatic ductal adenocarcinom… DOI 10.1002/ags3.12898↗
- Shin’ya Takahashi · 2 shared papers, 2025–2026 · strength 0.49
- Paper Survival benefit of adjuvant therapy completion with early initiation for patients with pancreatic ductal adenocarcinom… DOI 10.1002/ags3.12898↗
- Paper Clinical outcomes and recurrence patterns in pancreatic ductal adenocarcinoma diagnosed at an early stage: insights fro… DOI 10.1007/s00535-025-02340-x↗
- Takeshi Sudo · 2 shared papers, 2023–2026 · strength 0.44
- Paper Minichromosome maintenance 4 is associated with poor survival and stemness of patients with pancreatic cancer. DOI 10.1007/s00795-025-00438-y↗
- Paper Expression of kinesin family member C1 in pancreatic ductal adenocarcinoma affects tumor progression and stemness. DOI 10.1016/j.prp.2022.154277↗
- Akira Ishikawa · 2 shared papers, 2023–2026 · strength 0.44
- Paper Minichromosome maintenance 4 is associated with poor survival and stemness of patients with pancreatic cancer. DOI 10.1007/s00795-025-00438-y↗
- Paper Expression of kinesin family member C1 in pancreatic ductal adenocarcinoma affects tumor progression and stemness. DOI 10.1016/j.prp.2022.154277↗
- Masaru Furukawa · 2 shared papers, 2023–2026 · strength 0.41
- Paper Prognostic Impact of the Combined Use of CA19-9 and DUPAN-2 in Initially Unresectable Locally Advanced Pancreatic Adeno… DOI 10.1245/s10434-026-20710-4↗
- Paper Utility of Covered Self-Expanding Metal Stents for Biliary Drainage during Neoadjuvant Chemotherapy in Patients with Bo… DOI 10.3390/jcm12196245↗
- Shinya Nakamura · 2 shared papers, 2023–2026 · strength 0.39
- Paper Clinical outcomes and recurrence patterns in pancreatic ductal adenocarcinoma diagnosed at an early stage: insights fro… DOI 10.1007/s00535-025-02340-x↗
- Paper Utility of Covered Self-Expanding Metal Stents for Biliary Drainage during Neoadjuvant Chemotherapy in Patients with Bo… DOI 10.3390/jcm12196245↗
- Shinji Mii · 1 shared paper, 2026 · strength 0.27
- Wataru Yasui · 1 shared paper, 2026 · strength 0.27
- Yuto Fujiki · 1 shared paper, 2026 · strength 0.27
- Shinya Takahashi · 1 shared paper, 2026 · strength 0.26
- Kenta Baba · 1 shared paper, 2025 · strength 0.25
- Masanobu Yukutake · 1 shared paper, 2026 · strength 0.24
- Atsushi Yamaguchi · 1 shared paper, 2026 · strength 0.24
- Keiji Hanada · 1 shared paper, 2026 · strength 0.24
- Tomoyuki Minami · 1 shared paper, 2026 · strength 0.24
- Aya Kido · 1 shared paper, 2023 · strength 0.17
- Naohide Oue · 1 shared paper, 2023 · strength 0.17
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.